应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
OGN Organon & Co
休市中 11-22 16:00:00 EST
15.28
+0.39
+2.62%
盘后
15.32
+0.04
+0.26%
19:59 EST
最高
15.47
最低
14.94
成交量
254.91万
今开
14.94
昨收
14.89
日振幅
3.56%
总市值
39.35亿
流通市值
39.22亿
总股本
2.58亿
成交额
3,887万
换手率
0.99%
流通股本
2.57亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Organon & Co.2024财年第三财季实现净利润3.59亿美元,同比增加518.97%
市场透视 · 11-09
Organon & Co.2024财年第三财季实现净利润3.59亿美元,同比增加518.97%
Organon & Co.盘中异动 股价大跌5.08%报16.06美元
市场透视 · 11-05
Organon & Co.盘中异动 股价大跌5.08%报16.06美元
Organon & Co.盘中异动 急速下挫5.03%报17.16美元
市场透视 · 11-04
Organon & Co.盘中异动 急速下挫5.03%报17.16美元
Organon & Co.盘中异动 早盘快速拉升5.02%报18.83美元
市场透视 · 10-31
Organon & Co.盘中异动 早盘快速拉升5.02%报18.83美元
复宏汉霖地舒单抗生物类似药HLX14美国上市许可申请获FDA受理
美通社 · 10-31
复宏汉霖地舒单抗生物类似药HLX14美国上市许可申请获FDA受理
更正后的简报-出现自杀倾向后,EMA 开始对含有非那雄胺和度他雄胺的药物进行审查
Reuters · 10-04
更正后的简报-出现自杀倾向后,EMA 开始对含有非那雄胺和度他雄胺的药物进行审查
更新版 3-更正-欧盟监管机构审查抗眩晕药物,担心引发自杀念头
路透中文 · 10-04
更新版 3-更正-欧盟监管机构审查抗眩晕药物,担心引发自杀念头
更新版 2-更正-欧盟监管机构审查抗眩晕药物,担心引发自杀念头
Reuters · 10-04
更新版 2-更正-欧盟监管机构审查抗眩晕药物,担心引发自杀念头
BUZZ-Roivant因Organon同意以高达12亿美元的价格收购其部门而上涨
Reuters · 09-18
BUZZ-Roivant因Organon同意以高达12亿美元的价格收购其部门而上涨
更新版 1-Organon 拟以高达 12 亿美元的价格收购皮肤疗法开发商 Dermavant
Reuters · 09-18
更新版 1-Organon 拟以高达 12 亿美元的价格收购皮肤疗法开发商 Dermavant
Organon 将以高达 12 亿美元的价格收购疗法开发商 Dermavant
Reuters · 09-18
Organon 将以高达 12 亿美元的价格收购疗法开发商 Dermavant
"欧翎先锋"卓越药师峰会盛大召开
美通社 · 09-13
"欧翎先锋"卓越药师峰会盛大召开
礼来(LLY.US)与Organon(OGN.US)扩大偏头痛药物Emgality商业化协议
智通财经网 · 08-20
礼来(LLY.US)与Organon(OGN.US)扩大偏头痛药物Emgality商业化协议
Organon & Co.2024财年第二财季实现净利润1.95亿美元,同比减少19.42%
自选股智能写手 · 08-12
Organon & Co.2024财年第二财季实现净利润1.95亿美元,同比减少19.42%
Organon & Co.盘中异动 早盘股价大涨5.04%
自选股智能写手 · 08-07
Organon & Co.盘中异动 早盘股价大涨5.04%
BUZZ--美国股票走势-Lumen Technologies、Broadridge Financial、IDEXX
Reuters · 08-07
BUZZ--美国股票走势-Lumen Technologies、Broadridge Financial、IDEXX
BUZZ-Organon & Co 因下调财年销售预期而下跌
Reuters · 08-06
BUZZ-Organon & Co 因下调财年销售预期而下跌
异动解读 | Organon & Co二季度业绩不佳 股价盘中大跌7.38%
异动解读 · 08-06
异动解读 | Organon & Co二季度业绩不佳 股价盘中大跌7.38%
Organon & Co 公布截至 6 月的季度业绩 - 收益摘要
Reuters · 08-06
Organon & Co 公布截至 6 月的季度业绩 - 收益摘要
Organon & Co.盘中异动 大幅下跌5.40%报19.10美元
自选股智能写手 · 08-06
Organon & Co.盘中异动 大幅下跌5.40%报19.10美元
加载更多
公司概况
公司名称:
Organon & Co
所属市场:
NYSE
上市日期:
--
主营业务:
Organon & Co.是一家特拉华州公司,成立于2020年3月11日。Organon是一家基于科学的全球制药公司,通过一系列针对女性健康,生物仿制药和知名品牌的处方疗法,开发并提供创新的健康解决方案。他们的使命是成为世界领先的女性保健公司,每天为每个女性提供更好,更健康的服务。他们计划利用自身在生殖健康方面的优势,建立一系列健康解决方案,为从青春期到更年期及以后的妇女提供服务。
发行价格:
--
{"stockData":{"symbol":"OGN","market":"US","secType":"STK","nameCN":"Organon & Co","latestPrice":15.28,"timestamp":1732309200000,"preClose":14.89,"halted":0,"volume":2549098,"hourTrading":{"tag":"盘后","latestPrice":15.32,"preClose":15.28,"latestTime":"19:59 EST","volume":113904,"amount":1743780.16,"timestamp":1732323571896},"delay":0,"floatShares":256698448,"shares":257538875,"eps":5.040335,"marketStatus":"休市中","marketStatusCode":7,"change":0.39,"latestTime":"11-22 16:00:00 EST","open":14.94,"high":15.47,"low":14.94,"amount":38866176.228038,"amplitude":0.035594,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":5.040335,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732525200000},"adr":0,"adjPreClose":14.89,"dividendRate":0.073298,"preHourTrading":{"tag":"盘前","latestPrice":14.88,"preClose":14.89,"latestTime":"09:22 EST","volume":2310,"amount":34233.33375,"timestamp":1732285334045},"postHourTrading":{"tag":"盘后","latestPrice":15.32,"preClose":15.28,"latestTime":"19:59 EST","volume":113904,"amount":1743780.16,"timestamp":1732323571896},"volumeRatio":0.9419766530697601,"optionData":{"bulkOrders":[{"symbol":"OGN","call":false,"expireDate":1734670800000,"strike":"15.0","timestamp":1732306044659,"price":0.44999998807907104,"volume":1668,"amount":75060,"type":"-"}]},"impliedVol":0.1524,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/OGN","defaultTab":"news","newsList":[{"id":"2482485713","title":"Organon & Co.2024财年第三财季实现净利润3.59亿美元,同比增加518.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482485713","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482485713?lang=zh_cn&edition=full","pubTime":"2024-11-09 00:00","pubTimestamp":1731081631,"startTime":"0","endTime":"0","summary":"11月9日,Organon & Co.公布财报,公告显示公司2024财年第三财季净利润为3.59亿美元,同比增加518.97%;其中营业收入为15.82亿美元,同比增加4.15%,每股基本收益为1.39美元。从资产负债表来看,Organon & Co.总负债122.59亿美元,其中短期债务10.00百万美元,资产负债比为1.05,流动比率为1.71。机构评级:截至2024年11月9日,当前有8家机构对Organon & Co.目标价做出预测,其中目标均价为22.50美元,其中最低目标价为17.00美元,最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109000229abae6f9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109000229abae6f9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OGN"],"gpt_icon":0},{"id":"2481685971","title":"Organon & Co.盘中异动 股价大跌5.08%报16.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481685971","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481685971?lang=zh_cn&edition=full","pubTime":"2024-11-05 23:01","pubTimestamp":1730818871,"startTime":"0","endTime":"0","summary":"北京时间2024年11月05日23时01分,Organon & Co.股票出现异动,股价快速跳水5.08%。截至发稿,该股报16.06美元/股,成交量130.199万股,换手率0.51%,振幅4.49%。Organon & Co.股票所在的制药行业中,整体跌幅为0.62%。Organon & Co.公司简介:Organon & Co是一家以科学为基础的全球制药公司,通过在女性健康、生物仿制药和知名品牌中开发和提供处方疗法组合的健康解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105230112a218d415&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105230112a218d415&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065169927.USD","LU2065170008.USD","LU2065171311.SGD","LU2065171402.SGD","BK4007","BK4559","OGN","BK4588","BK4585"],"gpt_icon":0},{"id":"2480587678","title":"Organon & Co.盘中异动 急速下挫5.03%报17.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480587678","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480587678?lang=zh_cn&edition=full","pubTime":"2024-11-04 23:04","pubTimestamp":1730732681,"startTime":"0","endTime":"0","summary":"北京时间2024年11月04日23时04分,Organon & Co.股票出现异动,股价大幅跳水5.03%。截至发稿,该股报17.16美元/股,成交量51.8109万股,换手率0.20%,振幅4.73%。Organon & Co.股票所在的制药行业中,整体跌幅为0.49%。Organon & Co.公司简介:Organon & Co是一家以科学为基础的全球制药公司,通过在女性健康、生物仿制药和知名品牌中开发和提供处方疗法组合的健康解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104230441ab9ecde5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104230441ab9ecde5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU2065170008.USD","BK4585","OGN","LU2065171402.SGD","LU2065169927.USD","LU2065171311.SGD","BK4007","BK4559"],"gpt_icon":0},{"id":"2479228032","title":"Organon & Co.盘中异动 早盘快速拉升5.02%报18.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479228032","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479228032?lang=zh_cn&edition=full","pubTime":"2024-10-31 23:23","pubTimestamp":1730388227,"startTime":"0","endTime":"0","summary":"北京时间2024年10月31日23时23分,Organon & Co.股票出现异动,股价急速上涨5.02%。截至发稿,该股报18.83美元/股,成交量163.447万股,换手率0.63%,振幅5.24%。Organon & Co.股票所在的制药行业中,整体跌幅为0.56%。Organon & Co.公司简介:Organon & Co是一家以科学为基础的全球制药公司,通过在女性健康、生物仿制药和知名品牌中开发和提供处方疗法组合的健康解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031232347971a398f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031232347971a398f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065170008.USD","LU2065171311.SGD","LU2065169927.USD","LU2065171402.SGD","BK4588","BK4585","OGN","BK4559","BK4007"],"gpt_icon":0},{"id":"2479714519","title":"复宏汉霖地舒单抗生物类似药HLX14美国上市许可申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2479714519","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479714519?lang=zh_cn&edition=full","pubTime":"2024-10-31 09:49","pubTimestamp":1730339340,"startTime":"0","endTime":"0","summary":"上海和新泽西州泽西市2024年10月31日 /美通社/ -- 2024年10月30日,复宏汉霖与Organon共同宣布,在研PROLIA/XGEVA生物类似药HLX14的生物制品许可申请获美国食品药品监督管理局受理。复宏汉霖已于2022年与Organon达成授权许可和供应合作,授予其对包括HLX14在内的两款候选生物类似药在除中国以外的全球区域进行独家商业化的权益,协议覆盖美国、欧盟、加拿大等市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4544216_ZH44216_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["OGN","BK4585","BK4588","BK1161","LU2065171402.SGD","LU2065169927.USD","LU2065170008.USD","BK4007","LU2065171311.SGD","02696","BK4559"],"gpt_icon":0},{"id":"2472895963","title":"更正后的简报-出现自杀倾向后,EMA 开始对含有非那雄胺和度他雄胺的药物进行审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2472895963","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472895963?lang=zh_cn&edition=full","pubTime":"2024-10-04 20:46","pubTimestamp":1728045970,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) (更正简报来源为欧洲药品管理局,而非默克公司) 路透10月4日 - 欧洲药品管理局(EMA): * EMA:在对自杀意念和行为表示担忧后,已开始对含有非那雄胺和度他雄胺的药物进行审查 * EMA:最近,在丙磺舒和丙磺舒的产品信息中,自杀意念也被列为一种可能的副作用,发生频率不详 * 环境管理署:直接与医护专业人员沟通,告知医护专业人员凯帕拉和左乙拉西坦潜在的用药错误风险 * EMA:因改变定量注射器的容量而导致开普拉和左乙拉西坦的用药错误Eikon 的源文本: 更多公司报道:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU2065169927.USD","OGN","BK4588","BK4585","BK4007","LU2065171311.SGD","MRK","LU2065171402.SGD","BK4559"],"gpt_icon":0},{"id":"2472969227","title":"更新版 3-更正-欧盟监管机构审查抗眩晕药物,担心引发自杀念头","url":"https://stock-news.laohu8.com/highlight/detail?id=2472969227","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472969227?lang=zh_cn&edition=full","pubTime":"2024-10-04 20:36","pubTimestamp":1728045375,"startTime":"0","endTime":"0","summary":"更新版 3-更正-欧盟监管机构审查抗眩晕药物,担心引发自杀念头在第 7 段添加 Organon 的回应。路透10月4日 - 欧洲药品监管机构周五表示,它正在审查抗脱发药物,包括Organon公司的OGN.N保法止及其仿制药,因为这些药物有导致自杀念头的风险。欧洲药品管理局表示,它将在审查后建议是否撤销、暂停或保留这些药物在整个地区的上市许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241004:nL4T3LG0TN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK","BK4588","BK4007","LU2065170008.USD","BK4585","LU2065171311.SGD","BK4559","LU2065171402.SGD","OGN","LU2065169927.USD"],"gpt_icon":0},{"id":"2472956245","title":"更新版 2-更正-欧盟监管机构审查抗眩晕药物,担心引发自杀念头","url":"https://stock-news.laohu8.com/highlight/detail?id=2472956245","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472956245?lang=zh_cn&edition=full","pubTime":"2024-10-04 20:36","pubTimestamp":1728045375,"startTime":"0","endTime":"0","summary":" 路透10月4日 - 欧洲药品监管机构周五表示,它正在审查抗脱发药物,包括Organon公司的 保法止及其仿制药,因为这些药物有导致自杀念头的风险。欧洲药品管理局说,它将在审查后建议是否在整个地区撤销、暂停或保留这些药物的上市许可。几年后的2022年, 美国食品和药物管理局驳回了 ,要求将丙磺舒从市场上撤下,并下令在该药的标签上加上关于自杀 念头和行为的警告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0208291251.USD","LU1941712264.USD","IE00B1BXHZ80.USD","LU1066051811.HKD","IE00BJJMRZ35.SGD","LU2065171311.SGD","LU0265550359.USD","BK4588","BK4550","IE00BLSP4239.USD","IE0002141913.USD","IE00B4R5TH58.HKD","BK4516","LU1066051498.USD","LU1585245621.USD","LU0058720904.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0006306889.USD","LU1061106388.HKD","LU2065169927.USD","IE0009355771.USD","LU1066051225.USD","LU1093756325.SGD","LU0122379950.USD","IE00BBT3K403.USD","LU0203347892.USD","LU0965509283.SGD","LU2065171402.SGD","BK4559","LU1066053197.SGD","LU1934455863.HKD","LU1023059063.AUD","LU1093756168.USD","LU1116320737.USD","IE00BFTCPJ56.SGD","LU0203345920.USD","LU1917777945.USD","LU2065170008.USD","IE000M9KFDE8.USD","LU0211331839.USD","LU0320765489.SGD","LU0985320562.USD","OGN","LU0289739699.SGD","MRK","LU0861579265.USD","LU1116320901.HKD","LU1057294990.SGD","BK4585"],"gpt_icon":0},{"id":"2468583567","title":"BUZZ-Roivant因Organon同意以高达12亿美元的价格收购其部门而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2468583567","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468583567?lang=zh_cn&edition=full","pubTime":"2024-09-18 20:20","pubTimestamp":1726662022,"startTime":"0","endTime":"0","summary":" 9月18日 - ** Roivant Sciences 股价盘前上涨2.5%至12.35美元** 医疗保健公司Organon 称, ,该公司已同意以12亿美元收购皮肤疗法开发商Dermavant。** 该交易将使 OGN 获得 Dermavant 的银屑病药膏 VTAMA,该药膏于 2022 年 5 月获得美国 FDA 批准。** 作为交易的一部分,OGN 将支付 1.75 亿美元的预付款以及高达 9.5 亿美元的里程碑付款** OGN 预计在今年第四季度完成交易** 截至上次收盘,ROIV 股价年累计上涨 7.3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OGN","LU2065169927.USD","LU2065171311.SGD","ROIV","BK4139","LU2065170008.USD","BK4007","LU2065171402.SGD","BK4559","BK4588","BK4585"],"gpt_icon":0},{"id":"2468300195","title":"更新版 1-Organon 拟以高达 12 亿美元的价格收购皮肤疗法开发商 Dermavant","url":"https://stock-news.laohu8.com/highlight/detail?id=2468300195","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468300195?lang=zh_cn&edition=full","pubTime":"2024-09-18 19:55","pubTimestamp":1726660516,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) (第 2-4 段增加了交易细节) 路透9月18日 - 医疗保健公司Organon 周三表示,已同意以不超过12亿美元的价格收购Roivant 旗下皮肤疗法开发商Dermavant。Organon公司将支付1.75亿美元的预付款,以及7500万美元的里程碑付款,在达到某些商业里程碑时最高支付9.5亿美元。Dermavant 的 VTAMA 银屑病膏于 2022 年 5 月获得美国食品和药物管理局批准。银屑病是一种常见的慢性炎症性皮肤病。公司预计将在今年第四季度完成交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU2065169927.USD","OGN","BK4588","BK4007","BK4559","LU2065170008.USD","BK4585","ROIV","BK4139","LU2065171402.SGD"],"gpt_icon":0},{"id":"2468307175","title":"Organon 将以高达 12 亿美元的价格收购疗法开发商 Dermavant","url":"https://stock-news.laohu8.com/highlight/detail?id=2468307175","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468307175?lang=zh_cn&edition=full","pubTime":"2024-09-18 19:37","pubTimestamp":1726659434,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透9月18日 - 医疗保健公司Organon 周三表示,已同意以不超过12亿美元的价格收购Roivant 旗下的Dermavant公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OGN","LU2065169927.USD","LU2065171311.SGD","ROIV","BK4139","LU2065170008.USD","BK4007","LU2065171402.SGD","BK4559","BK4588","BK4585"],"gpt_icon":0},{"id":"2467771699","title":"\"欧翎先锋\"卓越药师峰会盛大召开","url":"https://stock-news.laohu8.com/highlight/detail?id=2467771699","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467771699?lang=zh_cn&edition=full","pubTime":"2024-09-13 15:02","pubTimestamp":1726210920,"startTime":"0","endTime":"0","summary":"弘扬药师专业风采,打造药店精细化慢病管理\"新名片\" 上海2024年9月13日 /美通社/ -- 今日,2024年第二届\"欧翎先锋\"卓越药师峰会圆满落幕。本届峰会上,由新华网主办,国际药学联合会、欧加隆共同参与的\"欧翎先锋我们身边了不起的医药零售人\"全国优秀零售药师事迹展,在各方的见证下,揭晓了首批优秀药师代表,并启动了新一轮优秀药师事迹的征集。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4505824_ZH05824_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2065170008.USD","LU2065171311.SGD","LU2065169927.USD","LU2065171402.SGD","BK4588","BK4585","OGN","BK4559","BK4007"],"gpt_icon":0},{"id":"2460989001","title":"礼来(LLY.US)与Organon(OGN.US)扩大偏头痛药物Emgality商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2460989001","media":"智通财经网","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460989001?lang=zh_cn&edition=full","pubTime":"2024-08-20 21:27","pubTimestamp":1724160456,"startTime":"0","endTime":"0","summary":"礼来与Organon已将偏头痛药物Emgality(galcanezumab)的商业化协议扩展至另外11个市场。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20240820/20240820212825_14995.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240820/20240820212825_14995.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1167292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE00BFTCPJ56.SGD","IE0009355771.USD","LU0096364046.USD","LU1035775433.USD","LU1280957306.USD","BK4007","IE0004445239.USD","LU0079474960.USD","LU0058720904.USD","BK4559","LU0114720955.EUR","LU0823416689.USD","LU1061106388.HKD","LU0122379950.USD","LLY","LU0882574055.USD","BK4516","IE00BJJMRZ35.SGD","LU0094547139.USD","LU0708995401.HKD","LU0820561909.HKD","LU0466842654.USD","LU0109391861.USD","LU0097036916.USD","LU1057294990.SGD","IE00B1BXHZ80.USD","LU0689472784.USD","GB00BDT5M118.USD","IE00BJT1NW94.SGD","LU0882574139.USD","LU0943347566.SGD","LU1551013342.USD","LU1623119135.USD","LU0006306889.USD","LU2065170008.USD","LU0061475181.USD","LU0471298694.HKD","IE0002141913.USD","BK4585","LU1064131342.USD","OGN","BK4588","IE00BJLML261.HKD","LU0256863811.USD","LU0820561818.USD","LU0385154629.USD","LU1069344957.HKD","LU1551013425.SGD","LU2065171311.SGD","LU0198837287.USD"],"gpt_icon":1},{"id":"2458469739","title":"Organon & Co.2024财年第二财季实现净利润1.95亿美元,同比减少19.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458469739","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458469739?lang=zh_cn&edition=full","pubTime":"2024-08-12 00:14","pubTimestamp":1723392890,"startTime":"0","endTime":"0","summary":"8月12日,Organon & Co.公布财报,公告显示公司2024财年第二财季净利润为1.95亿美元,同比减少19.42%;其中营业收入为16.07亿美元,同比减少0.06%,每股基本收益为0.76美元。从资产负债表来看,Organon & Co.总负债120.10亿美元,其中短期债务9.00百万美元,资产负债比为1.02,流动比率为1.64。机构评级:截至2024年8月12日,当前有8家机构对Organon & Co.目标价做出预测,其中目标均价为22.50美元,其中最低目标价为17.00美元,最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240812001452959044ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240812001452959044ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OGN"],"gpt_icon":0},{"id":"2457422468","title":"Organon & Co.盘中异动 早盘股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457422468","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457422468?lang=zh_cn&edition=full","pubTime":"2024-08-07 21:57","pubTimestamp":1723039058,"startTime":"0","endTime":"0","summary":"北京时间2024年08月07日21时57分,Organon & Co.股票出现异动,股价急速上涨5.04%。截至发稿,该股报19.59美元/股,成交量27.7894万股,换手率0.11%,振幅3.54%。Organon & Co.股票所在的制药行业中,整体跌幅为0.50%。Organon & Co.公司简介:Organon & Co是一家以科学为基础的全球制药公司,通过在女性健康、生物仿制药和知名品牌中开发和提供处方疗法组合的健康解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807215739941ff0ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807215739941ff0ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OGN","LU2065171402.SGD","BK4588","LU2065170008.USD","BK4585","BK4007","LU2065169927.USD","LU2065171311.SGD","BK4559"],"gpt_icon":0},{"id":"2457732550","title":"BUZZ--美国股票走势-Lumen Technologies、Broadridge Financial、IDEXX","url":"https://stock-news.laohu8.com/highlight/detail?id=2457732550","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457732550?lang=zh_cn&edition=full","pubTime":"2024-08-07 00:30","pubTimestamp":1722961818,"startTime":"0","endTime":"0","summary":"美东时间12:14,道琼斯工业平均指数 上涨1.22%,报39,175.66点。标普500指数 上涨1.74%,报5276.66点;纳斯达克综合指数 上涨1.81%,报16492.856点。** CVS Health Corp :下跌 0.5%BUZZ - 巴克莱认为,成本上升趋势对 CVS 第二季度和全年利润构成风险 ** Jacobs Solutions Inc :上涨 1.2%BUZZ - 在第三季度收入超预期后上涨 ** IDEXX Laboratories Inc :上涨 4.3%BUZZ - 在预期下调并不像人们担心的那样糟糕之后,在缓解性反弹中上涨 标准普尔 500 指数的 11 个主要行业:通信服务","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCK","ZTS","SRPT","CAT","DDM","TQQQ","ZI","DXD",".DJI","MKTX","BVS","OGN","TAP","NQmain","J","CSX","EXPD","SQQQ","HIMS","BAX",".IXIC","KVUE",".SPX","TALK","BMRN","TDG","LUMN","FIS","DJX","IDXX","PSQ","HSIC","BUZZ","QID","UDOW","GEHC","BR","SDOW","MNQmain","MPC","VNO","SPWR","CVS","ELEV"],"gpt_icon":1},{"id":"2457023094","title":"BUZZ-Organon & Co 因下调财年销售预期而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2457023094","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457023094?lang=zh_cn&edition=full","pubTime":"2024-08-06 22:01","pubTimestamp":1722952888,"startTime":"0","endTime":"0","summary":" 8月6日 - ** 专注于女性健康的 Organon 股价下跌 9%,报 18.31 美元** 公司目前预计全年收入在62.5亿至64.5亿美元之间,而之前的预期为62亿至65亿美元。** Organon 公布第二季度收入为 16.1 亿美元,预计为 16.3 亿美元。** 公司妇女保健产品的销售额增长 3%,达到 4.49 亿美元,与预期一致 ** Organon 既有品牌部门和生物仿制药业务的收入低于预期** 截至上一交易日收盘,股价累计上涨 40","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","LU2065169927.USD","LU2065171311.SGD","OGN","BUZZ","BK4559","LU2065171402.SGD","LU2065170008.USD","BK4588"],"gpt_icon":0},{"id":"1152349908","title":"异动解读 | Organon & Co二季度业绩不佳 股价盘中大跌7.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152349908","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152349908?lang=zh_cn&edition=full","pubTime":"2024-08-06 21:43","pubTimestamp":1722951811,"startTime":"0","endTime":"0","summary":"制药公司Organon & Co今日公布了2024年第二季度财报,业绩数据令人失望,导致其股价盘中大跌7.38%。\n\n财报显示,Organon & Co本季度调整后每股收益为1.12美元,低于去年同期的1.31美元。营业收入为16.1亿美元,同比下降0.1%,也未能达到分析师预期的16.3亿美元。公司本季度净收入为1.95亿美元,较上年同期有所下降。\n\n值得注意的是,在过去三个月里,分析师对Organon & Co的平均盈利预期下调了约6.3%,显示出对公司未来前景的担忧。目前分析师对该公司股票的平均评级为\"持有\"。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OGN"],"gpt_icon":0},{"id":"2457400330","title":"Organon & Co 公布截至 6 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2457400330","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457400330?lang=zh_cn&edition=full","pubTime":"2024-08-06 21:32","pubTimestamp":1722951178,"startTime":"0","endTime":"0","summary":" * Organon & Co 公布的截至6月底的季度调整后每股收益为1.12美元,低于去年同期的每股收益1.31美元。八位分析师对该季度的平均预期为每股收益 1.08 美元。华尔街预期为每股收益 93 美分至 1.24 美元。* Organon & Co 公司公布的本季度每股收益为 75 美分。* 公司报告的季度净收入为 1.95 亿美元。* Organon & Co 的股价本季度下跌了 2.5%,今年迄今为止上涨了 40.0%。华尔街对 Organon & Co 的 12 个月目标价中位数为 22.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Organon & Co 公布截至 6 月的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU2065171402.SGD","OGN","BK4588","BK4559","BK4585","LU2065170008.USD","LU2065169927.USD","BK4007"],"gpt_icon":0},{"id":"2457028730","title":"Organon & Co.盘中异动 大幅下跌5.40%报19.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457028730","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457028730?lang=zh_cn&edition=full","pubTime":"2024-08-06 21:32","pubTimestamp":1722951141,"startTime":"0","endTime":"0","summary":"北京时间2024年08月06日21时32分,Organon & Co.股票出现异动,股价快速下跌5.40%。截至发稿,该股报19.10美元/股,成交量8.1822万股,换手率0.03%,振幅3.37%。Organon & Co.股票所在的制药行业中,整体涨幅为0.90%。Organon & Co.公司简介:Organon & Co是一家以科学为基础的全球制药公司,通过在女性健康、生物仿制药和知名品牌中开发和提供处方疗法组合的健康解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240806213221aefd8581&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240806213221aefd8581&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065170008.USD","LU2065171311.SGD","LU2065169927.USD","LU2065171402.SGD","BK4588","BK4585","OGN","BK4559","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.organon.com","stockEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.1121},{"period":"3month","weight":-0.3166},{"period":"6month","weight":-0.272},{"period":"1year","weight":0.3594},{"period":"ytd","weight":0.0596}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Organon & Co.是一家特拉华州公司,成立于2020年3月11日。Organon是一家基于科学的全球制药公司,通过一系列针对女性健康,生物仿制药和知名品牌的处方疗法,开发并提供创新的健康解决方案。他们的使命是成为世界领先的女性保健公司,每天为每个女性提供更好,更健康的服务。他们计划利用自身在生殖健康方面的优势,建立一系列健康解决方案,为从青春期到更年期及以后的妇女提供服务。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.093787},{"month":2,"riseRate":0.666667,"avgChangeRate":0.009437},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.00802},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.012449},{"month":5,"riseRate":0.666667,"avgChangeRate":0.03585},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.022403},{"month":7,"riseRate":0.5,"avgChangeRate":0.002701},{"month":8,"riseRate":0.5,"avgChangeRate":0.022289},{"month":9,"riseRate":0,"avgChangeRate":-0.141453},{"month":10,"riseRate":0.5,"avgChangeRate":0.018308},{"month":11,"riseRate":0,"avgChangeRate":-0.157931},{"month":12,"riseRate":1,"avgChangeRate":0.129665}],"exchange":"NYSE","name":"Organon & Co","nameEN":"Organon & Co"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Organon & Co(OGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Organon & Co(OGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Organon & Co,OGN,Organon & Co股票,Organon & Co股票老虎,Organon & Co股票老虎国际,Organon & Co行情,Organon & Co股票行情,Organon & Co股价,Organon & Co股市,Organon & Co股票价格,Organon & Co股票交易,Organon & Co股票购买,Organon & Co股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Organon & Co(OGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Organon & Co(OGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}